CTLA4 and melanoma: Our lab recently demonstrated that immune checkpoint blockade with combined anti-PD-1 plus anti-CTLA-4 therapy inhibits B16 and Ret melanoma growth in the brain only if the mice are simultaneously bearing tumors of the same type under the skin, while the therapy failed in mice with intracranial tumors only (Taggart et al., 2018).